〔Abstract〕 Objective To compare the differences in clinical outcomes of ovulation induction with highly purified human menopausal gonadotropin(HP-hMG, Menopur) versus recombinant human follicle stimulating hormone(rFSH, Gonal-F) in normal ovarian responder patients treated with the GnRH-antagonist protocol. Methods Patients treated with the GnRH-antagonist protocol were retrospectively analyzed and divided by gonadotropin(Gn) usage into HP-hMG group and rFSH group. The basic characteristics, ovulation induction method, laboratory indexes, and clinical outcomes were compared between the two groups. Results A total of 614 normal ovarian responder patients were enrolled in the study, with 216 in the HP-hMG group and 398 in the rFSH group. There was no significant difference inPlevels and LH levels on the hCG trigger day between the two groups. However, the E2levels on the hCG trigger day were significantly lower in the HP-hMG group(P<0.001). Moreover, the HP-hMG group had a higher biochemical pregnancy rate(69.23%vs63.51%) and clinical pregnancy rate(66.67%vs59.46%) compared to the rFSH group.The incidence of OHSS in the HP-hMG group(2.31%vs3.02%) showed a decreasing trend compared to the rFSH group. Conclusion Compared to rFSH, HP-hMG offers distinct advantages in reducing the incidence of OHSS and improving pregnancy outcomes in normal ovarian responder patients undergoing pituitary suppression with the GnRH-antagonist protocol.